Close Menu

NEW YORK – Three investment banks on Monday initiated coverage of rare disease genetic testing and services company Centogene with bullish outlooks.

BTIG initiated coverage of Rostock, Germany-based Centogene with a Buy rating on its stock and an $18 price target, while SVB Leerink rated the firm's shares Outperform and put a price target of $21. Evercore ISI began coverage of Centogene with an Outperform rating on its stock and a $17 price target.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.

Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research. 

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.